Comparing laparoscopic and open surgery for advanced gastric cancer
Official title: Comparison of Laparoscopic Versus Open Total Gastrectomy for Locally Advanced Gastric Cancer: a Prospective Randomized Control Trial
Run by University Medical Center Ho Chi Minh City (UMC) · NCT06202105 · Data updated 2026-11-12
This study is testing whether laparoscopic surgery is safer and more effective than traditional open surgery for patients with advanced gastric cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | University Medical Center Ho Chi Minh City (UMC) Academic / other |
| Locations | 3 sites (Bien Hoa, Dong Nai and 2 other locations) |
| Status | Recruiting |
| Started | August 2, 2024 |
| Main results expected | August 2, 2032 |
| Study ends | August 2, 2032 |
| Registry record updated | January 1, 2025 |
| Trial ID | NCT06202105 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 with confirmed gastric adenocarcinoma requiring total gastrectomy and classified as cT2-4aNanyM0.
✕Probably not a fit
Patients with concurrent cancers, bulky lymph node metastasis, or those requiring combined esophagectomy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to compare the short- and mid-term outcomes of laparoscopic total gastrectomy (LTG) versus open total gastrectomy (OTG) in patients with locally advanced gastric cancer (GC). Gastric cancer is a major health concern, and while OTG has been the standard surgical approach, advancements in laparoscopic techniques have prompted a need for this comparison. The study will include patients with confirmed gastric adenocarcinoma who require total gastrectomy, assessing the safety and efficacy of LTG in this context. The research is particularly relevant as there is limited data on the long-term outcomes of LTG for advanced cases of gastric cancer.
Why it matters
Potential benefit: If successful, this study could provide evidence supporting the use of laparoscopic techniques for improved surgical outcomes in patients with advanced gastric cancer.
How similar studies have gone: Previous studies have shown the advantages of laparoscopic techniques for early gastric cancer, but this approach for advanced cases is still being evaluated and lacks extensive prior research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologic finding by gastric endoscopy: confirmed gastric adenocarcinoma * Age: 18 - 80 year old * Tumor required total gastrectomy for radical treatment * Preoperative cancer stage (CT scan stage): cT2-4aNanyM0 * ASA score: ≤ 3 * Informed consent patients (explanation about our clinical trials is provided to the patients or patrons, if patient is not available) Exclusion Criteria: * Concurrent cancer or patient who was treated due to other cancer before the patient was diagnosed gastric cancer * Bulky lymph node andd/or Para-aortic lymph node metastasis * Combined esophagectomy due to invading to the esophagus * Pregnant patient
Where it's running
-
Dong Nai General Hospital
Bien Hoa, Dong Nai, Vietnam Recruiting -
University Medical Center Ho Chi Minh City
Ho Chi Minh City, Vietnam Recruiting -
108 Military Central Hospital
Hà Nội, Vietnam Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.